Spondyloarthritis & psoriatic arthritis
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies
Authors' conclusion
Bimekizumab demonstrated sustained high levels of efficacy and tolerability to 3 years, supporting its suitability for long-term treatment in bDMARD-naïve and TNFi-IR patients with PsA.
Study context
- Population
- Patients with PsA, bDMARD-naïve or TNFi-IR546/299 completed year 3
- Comparison
- Bimekizumab 160 mg s.c. every 4 weeks in bDMARD-naïve and TNFi-IR patients with PsA, to 3 years
Methodological detailsBE VITAL, modified non-responder or multiple imputation, or as observed, Study completers could enrol in the BE VITAL open-label extension
- BE VITAL
- Modified non-responder or multiple imputation, or as observed
- Study completers could enrol in the BE VITAL open-label extension
Primary result
As reported in the abstract
ACR50 response · year 3
Further findings
ACR50 response · year 1
Swollen joint count resolution · year 1
Swollen joint count resolution · year 3
PASI 100 (100% improvement from baseline) · year 1
PASI 100 (100% improvement from baseline) · year 3
Safety
Treatment-emergent adverse events, exposure-adjusted incidence rate/100 patient-years
Treatment-emergent adverse events, exposure-adjusted incidence rate/100 patient-years
- Consistent with year 1; no new safety signals identified
Original publication
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies. Rheumatology (Oxford). Published 16 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →